Judge Accepts Amgen's (AMGN) $762M Plea in Civil Liability Case
Article
Related Press Releases (1)
Related Articles (1)
Related SEC Filings (1)
Stock Quotes (1)
Comments (0)
Tweet
Send to a Friend
Get Alerts AMGN Hot Sheet
Price: $104.24 +2.02%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
Revenue Growth %: +3.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
Revenue Growth %: +3.7%
Trade AMGN Now!
Amgen's (NASDAQ: AMGN) previously announced ettlement agreement with the U.S. government, 49 states and the District of Columbia was accepted by the judge today.
Previously, Amgen disclosed a $612 payment to resolve its civil liability related to certain promotional practices related to the drugs Aranesp (darbepoetin alfa), EPOGEN (epoetin alfa), NEUPOGEN (Filgrastim), Neulasta (pegfilgrastim), Enbrel (etanercept) and Sensipar (cinacalcet) as alleged in the unsealed qui tam complaints and $150 million to resolve its criminal liability relating to the marketing of Aranesp. The Company also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Previously, Amgen disclosed a $612 payment to resolve its civil liability related to certain promotional practices related to the drugs Aranesp (darbepoetin alfa), EPOGEN (epoetin alfa), NEUPOGEN (Filgrastim), Neulasta (pegfilgrastim), Enbrel (etanercept) and Sensipar (cinacalcet) as alleged in the unsealed qui tam complaints and $150 million to resolve its criminal liability relating to the marketing of Aranesp. The Company also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Bank Leumi le-Israel Moves to Terminate Credit Lines for Elbit Imaging (EMITF)
- Pfizer (PFE) Discontinues Phase 3 Study of Inotuzumab Ozogamicin
- Procter & Gamble (PG) Sues CAO Group Over Crest Whitestrips Patents
Create E-mail Alert Related Categories
Corporate News, FDA, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
